HOW TO PREVENT DISMISSAL OF YOUR GENERIC ZANTAC CASES
OUR WHITEBOARD WEDNESDAY ON DECEMBER 16TH IS AN ABSOLUTE MUST FOR YOUR ZANTAC CASES.
Are you aware that the DEFENDANTS will be actively attempting to have your Plaintiff’s cases thrown out by claiming that they have stopped marketing that particular Zantac/Ranitidine product based on their “end marketing” dates. YOU WILL UNDERSTAND HOW TO COUNTER THIS TACTIC AND SAVE YOUR CASES after participating in Whiteboard Wednesday on 12/16 (2PM-4PM EST).
Mass Tort Nexus has unraveled and uncovered a far-reaching CONSPIRACY (and identified the major conspirators) that produced, packaged, distributed and sold approximately 1,000 various Ranitidine products by employing a scheme involving obtaining multiple National Drug Code’s (NDC), for finished products with branding and labeling that was never approved by the FDA and for that matter, could not be approved by the FDA. Per (21 CFR §207.37 (a)(2), Assignment of an NDC number does not in any way denote FDA approval of the product. Any representation that “creates an impression of official approval because of possession of an NDC number is misleading and constitutes misbranding.
IT’S A BOMBSHELL!
In a nutshell, a single Ranitidine drug maker would obtain FDA approval for the generic (ANDA) that included labeling for a single finished product, (in various sizes/counts) for sale to a retail class of consumers. That drug maker would then fill and ship large containers (drums of up to 60,000 pills) to a repackaging company. The repackaging company would repackage at a smaller scale with retail store branding and labeling. This “repackaging” was never approved by the FDA. These are counterfeit finished drugs. Under NO circumstances is a repackaged product to end up on a retail shelf as an OTC drug in any store…it is illegal.
The creation of counterfeit finished drug products as described above, is a Federal crime. In violation of 21 U.S. Code § 331 (k), § 331 (a) and § 331 (b) and is punishable under of 21 U.S. Code § 333 by up to 10 years in prison and a $10,000.00 fine for each individual unit of product entered into the stream of commerce.
ONCE YOU UNDERSTAND THE LAWS/REGULATIONS SURROUNDING THIS, YOU WILL BE ARMED TO IDENTIFY A COUNTERFEIT RANITIDINE PRODUCT IN VIOLATION OF 21 U.S. Code § 331. THRU REVIEW OF THE SPL (STRUCTED PRODUCT LABELING) INFORMATION AND OTHER EVIDENCE IN OUR POSESSION. WITH THIS INFORMATION AND EVIDENCE IN HAND, YOU WILL BE ABLE TO DISCREDIT ANY AVERMENTS OF THESE DEFENDANTS CLAIMING THAT THEY HAD CEASED MARKETING A GIVEN PRODUCT AT THE TIME YOUR CLIENT CLAIMS TO HAVE PURCHASED THAT PRODUCT.
To provide clarity on WHAT THE DEFENDANTS ARE HIDING, you will receive John Ray’s White Paper prior to 12/16 for your review AND all of this ground-breaking information will be discussed in further detail on the Zantac/Ranitidine Whiteboard Wednesday (2PM-4PM EST).
REGISTER NOW-WE ARE APPROACHING CAPACITY.